22.626 articles found

Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders.

Mosley RL, Gendelman HE.

Exp Neurol · 2010-01-04

DOI: 10.1016/j.expneurol.2009.12.018PMID: 20044993

Dynamic causal modelling of effective connectivity from fMRI: are results reproducible and sensitive to Parkinson's disease and its treatment?

Rowe JB, Hughes LE, Barker RA, Owen AM.

Neuroimage · 2010-01-04

DOI: 10.1016/j.neuroimage.2009.12.080PMID: 20056151

Clinical and PET imaging studies in Parkinson's disease motor and non-motor complications : serotonergic and dopamimergic mechanisms and applications in treatment

Politis M.

· 2010-01-01

Pre-clinical experimental models for tauopathies : assessment of novel treatments

Melis V.

· 2010-01-01

A feasibility study of differential delivery of levodopa ester and benserazide using site-specific intestinal loops in rats.

Itoh S, Oo C.

J Pharm Sci · 2010-01-01

DOI: 10.1002/jps.21822PMID: 19455628

Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson's disease.

Santamato A, Ranieri M, Panza F, Zoccolella S, Frisardi V, Solfrizzi V, Amoruso MT, Amoruso L, Fiore P.

J Neurol · 2010-01-01

DOI: 10.1007/s00415-009-5310-4PMID: 19763384

Levodopa inhibits the development of form-deprivation myopia in guinea pigs.

Mao J, Liu S, Qin W, Li F, Wu X, Tan Q.

Optom Vis Sci · 2010-01-01

DOI: 10.1097/opx.0b013e3181c12b3dPMID: 19901858

Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease.

Mizuno Y, Kondo T, Kuno S, Nomoto M, Yanagisawa N.

Clin Neuropharmacol · 2010-01-01

DOI: 10.1097/wnf.0b013e3181bbf45cPMID: 19935410

Targeted chemotherapy in drug-resistant tumors, noninvasive imaging of P-glycoprotein-mediated functional transport in cancer, and emerging role of Pgp in neurodegenerative diseases.

Sivapackiam J, Gammon ST, Harpstrite SE, Sharma V.

Methods Mol Biol · 2010-01-01

DOI: 10.1007/978-1-60761-416-6_8PMID: 19949924

Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?

Vallette S, Serri K, Serri O.

Expert Rev Cardiovasc Ther · 2010-01-01

DOI: 10.1586/erc.09.167PMID: 20014934

Parkinson disease: Another player in gene therapy for Parkinson disease.

Kaplitt MG.

Nat Rev Neurol · 2010-01-01

DOI: 10.1038/nrneurol.2009.214PMID: 20057491

INPH and Parkinson disease: differentiation by levodopa response.

Morishita T, Foote KD, Okun MS.

Nat Rev Neurol · 2010-01-01

DOI: 10.1038/nrneurol.2009.195PMID: 20057498